Correlation Between Bristol Myers and Cellectis

Can any of the company-specific risk be diversified away by investing in both Bristol Myers and Cellectis at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bristol Myers and Cellectis into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Bristol Myers Squibb and Cellectis SA, you can compare the effects of market volatilities on Bristol Myers and Cellectis and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bristol Myers with a short position of Cellectis. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bristol Myers and Cellectis.

Diversification Opportunities for Bristol Myers and Cellectis

-0.71

Correlation Coefficient

Bristol Myers  Cellectis

Pay attention - limited upside

The 3 months correlation between Bristol and Cellectis is -0.71. Overlapping area represents the amount of risk that can be diversified away by holding Bristol Myers Squibb and Cellectis SA in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cellectis SA and Bristol Myers is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bristol Myers Squibb are associated (or correlated) with Cellectis. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cellectis SA has no effect on the direction of Bristol Myers i.e., Bristol Myers and Cellectis go up and down completely randomly.

Pair Corralation between Bristol Myers and Cellectis

Considering the 90-day investment horizon Bristol Myers Squibb is expected to generate 0.63 times more return on investment than Cellectis. However, Bristol Myers Squibb is 1.6 times less risky than Cellectis. It trades about 0.14 of its potential returns per unit of risk. Cellectis SA is currently generating about -0.01 per unit of risk. If you would invest  4,996  in Bristol Myers Squibb on September 1, 2024 and sell it today you would earn a total of  926.00  from holding Bristol Myers Squibb or generate 18.53% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Bristol Myers Squibb  vs.  Cellectis SA

Bristol Myers Squibb

Risk-Adjusted Performance

11 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Bristol Myers Squibb are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak primary indicators, Bristol Myers showed solid returns over the last few months and may actually be approaching a breakup point.

Cellectis SA

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Cellectis SA has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable essential indicators, Cellectis is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors.

Pair Trading with Bristol Myers and Cellectis

The main advantage of trading using opposite Bristol Myers and Cellectis positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bristol Myers position performs unexpectedly, Cellectis can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cellectis will offset losses from the drop in Cellectis' long position.

The idea behind Bristol Myers Squibb and Cellectis SA pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.